CARLSBAD, CA – December 14, 2010 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB: INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today through its wholly owned subsidiary, BlackBox Semiconductor, Inc., that it’s recently licensed “electronic glue” chemistry will enable high efficiency solar cells to be fabricated from semiconductor nanocrystals with low cost roll-to-roll processing.

For years it has been theorized that the tunable properties of semiconductor nanocrystals could enable a next generation of highly efficient and low cost solar cells. However, to date, efficiencies of such devices have been extremely low – mostly due to the fact that the “electronic coupling” between nanocystals has been poor. This means that when energy is created, it does not flow very well – certainly not as well as silicon – which means that minimal amounts of the energy collected are ultimately harvested and turned into power. “Electronic glue” solves this critical technical barrier.

In a solar cell, light is harvested by the semiconductor material (typically silicon) which produces charges. In order to produce electricity, these charges need to flow easily through the material. Solar cells have been made from nanomaterials, but the efficiency improving properties of the nanomaterials have to be eliminated by melting them together because this is the only way for charge carriers to flow. Nanocrystals have been great light harvesters but have historically have provided a poor path for charges to flow.

The University of Chicago technology, invented by Dr. Dmitri Talapin, solves this problem by modifying the nanocrystals with an “electronic glue” that allows charges to flow more easily between particles, thus giving the device the potential power and efficiency of bulk semiconductors while enjoying the benefits of the small size and flexibility of the semiconductor nanocrystals. This will lead to a device being manufactured with the ultimate combination of high efficiency and low cost, roll-to-roll production.

“Shrink has done a considerable amount of work in the semiconductor nanocrystal realm, always running into the headwinds electronic coupling issues. We believe that Dr. Talapin’s “electronic glue” technology is going to be a game changer as we ready our resources to turn this technology into products that make a difference in people’s lives,” said Shrink CEO Mark L. Baum.
The Large and Growing Solar Market Needs a Game Changing Next Generation Commercial Technology

The global solar market is poised to rebound in the coming years and ultimately eclipse the $83 billion market in 2014, according to U.S. Solar Energy Market World Data, 2nd Edition by leading industrial market research firm SBI Energy.

Future growth is attributed to the anticipated strength of strong photovoltaic module sales in countries such as the United States, Germany, and China, in addition to a continuing strong solar thermal market in the two latter countries. Compound annual growth rate (CAGR) will exceed of 40% through 2014 in many segments of the solar market.

According to Norman Deschamps, SBI Energy analyst, “The strong growth for solar as a whole is going to begin in 2010 as sales in the photovoltaic sector continue to accelerate and declines in module and system component prices become far more moderate, along the lines of a 10% to 15% drop rather than the tumultuous 25% to 40% drop experienced in 2009. Equally noteworthy is the reality that global concentrated solar power installations are just getting started and we predict tremendous growth in the segment beginning in 2012.”

In the U.S., the solar market has come far since its inception over 30 years ago, but still has a long way to go. While growth has been spectacular since 2002, solar power continues to hold just a fractional share — under 1% — of U.S. energy production. Nevertheless, the U.S. has the greatest potential to increase its position in the solar market. The U.S. photovoltaic market was up an estimated 6% in 2009 to almost $4 billion and photovoltaic installations rose to 469 megawatts, according to SBI Energy. By 2014, photovoltaic installations are forecast to reach 7,600 megawatts by building on renewed interest in solar from utilities and the extension of the solar tax credit.

To learn more about Dr. Talapin’s work, Google: “electronic glue”

About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company’s unique NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology and solar technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.
See also:

http://www.shrinksolar.com/blog/

http://www.shrinknano.com/products/product-tools

http://www.shrinknano.com/products/product-diagnostics

http://www.shrinknano.com/tech

http://www.shrinknano.com/tr35-a-children%E2%80%99s-toy-inspires-a-cheap-easy-production-method-for-high-tech-diagnostic-chips

New ‘electronic glue’ promises less expensive semiconductors
Dmitri Talapin

Shrink Nanotechnologies announced today that it had formed a wholly owned subsidiary called BlackBox Semiconductor, Inc. (“BlackBox”), and that BlackBox has entered into a worldwide multi-year exclusive license with the University of Chicago, licensing work based on Assistant Professor of Chemistry, Dmitri Talapin’s “electronic glue” chemistry. The license covers all applications except for thermoelectric applications.

“We are pleased to announce that we have reached an agreement with the University of Chicago to license intellectual property that we believe has the potential to radically change the economics in a number of burgeoning large industries, including printed semiconductors, roll-to-roll printed solar cells and a new generation of low cost printed nano-sensors. This technology and the ongoing work by its inventors is widely acclaimed and has been published on multiple occasions in the world’s most prestigious academic journals, including Science, Nature and the Journal of the American Chemical Society,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

Semiconductors have served as choice materials for many electronic and optical devices because of their physical properties. Semiconductor nanocrystals are mass-produceable and have promise for use in device manufacturing via inkjet printing and other solution-based processes.

Commercial solar cells, computer chips and other semiconductor technologies typically use large semiconductor crystals, such as silicon. These materials and the processes required to manufacture commercial products from them are expensive and can make large-scale applications such as rooftop solar-energy collectors prohibitive. Also, material such as silicon is not “tunable” which means they can only harness a relatively narrow part of the available solar spectrum.

While semiconductor nanocrystals are very good receptors of light which could be converted to electricity (in the case of a solar cell), the collection of electrical charges from individual semiconductor nanocrystals cannot be accomplished efficiently using existing technologies because the semiconductor nanocrystals themselves are not great “carriers” of the electricity produced by the light they receive.

Prior to Dr. Talapin’s innovation – which has been called “electronic glue” – nanocrystals were unable to efficiently transfer their electric charges to one another because of the surface ligands which are used in the nanocrystal synthesis process. These surface ligands are bulky, insulating organic molecules that cap nanocrystals. Dr. Talapin’s “electronic glue” solves the ligand problem by substituted insulating organic molecules with novel inorganic molecules and dramatically increases the electronic coupling between nanocrystals.

Baum concluded, “We have been working on nanocrystal applications since we started Shrink. We have an appreciation of the shortcomings of nanocrystals for these ‘killer apps’ like solar cells and other large market semiconductor applications. We believe what we have is the potential to build low cost tunable solid state semiconductors which perform like bulk semiconductors, but which maintain all of the tremendous benefits that semiconductor nanocrystals offer. This license is an important part of how we intend to drive value for our shareholders, as we build our business by executing on our unique model. Over the coming months, we will begin to discuss this powerful technology and our plans to deploy resources to develop targeted commercial applications with it.”

To learn more about Dr. Talapin’s work, Google: “electronic glue”

announced today that it has entered into a multi-year development and manufacturing agreement with EV Group, a 30 year old Austria-based leader in the nano-imprint lithography process designing and equipment manufacturing. The mutually exclusive two year agreement calls for EV Group and Shrink to develop and manufacture Shrink’s structured substrates for its StemDisc stem cell and cell culturing platform.

Some of the key design features of the StemDisc are:

1. Each StemDisc contains an eight-well footprint, and each well contains approximately 850 individual honeycomb shaped microwell cell culturing environments;
2. Each StemDisc microwell environment is approximately 450 microns across and over 100 microns deep, and is made from sub 200 micron thick optically transparent polymers, allowing the researchers’ microscope unprecedented access to the biological sample; and
3. The bottom aspect of the cell culturing environment is round, mimicking the natural shape of many of the tissue samples which may be studied in the StemDisc.

“We are pleased to announce Shrink’s relationship with EV Group, a world class nanotechnology applications developer and equipment manufacturer with a global presence. Over the past two years, Shrink StemDisc product footprint will serve as a platform for our entry into the growing cell culturing business. We believe that StemDisc offers unique competitive advantages relative to its peers and are excited as an organization as we roll out our initial products later this year and into the first quarter of next year,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

Baum added, “Throughout the development process, we have counseled with EV Group and they have assisted us in creating manufacturing solutions that will allow Shrink to move from the prototype stage to the ability make many thousands of devices. As important, our relationship with EV Group has been structured for us to move beyond our initial product, the StemDisc450, as we add new products to the StemDisc family of products.”

EV Group VP and General Manager of North America stated, “Our Agreement with Shrink follows many months of work between Shrink’s StemDisc development group and our staff in Tempe, Arizona. Our team’s dedication to Shrink’s desire to create a robust process to manufacture many thousands of StemDisc devices in an efficient and cost effective process using EV Group’s state-of-the-art Application Lab has borne fruit as we begin to make devices as soon as the end of this year. This project will hopefully be one of many we work on with Shrink as EV Group leverages its significant intellectual capital in the form of process development for small and medium sizes business around the world.”

About EV Group

EV Group (EVG) is a world leader in wafer-processing solutions for semiconductor, MEMS and nanotechnology applications. Through close collaboration with its global customers, the company implements its flexible manufacturing model to develop reliable, high-quality, low-cost-of-ownership systems that are easily integrated into customers’ fab lines. Key products include wafer bonding, lithography/nanoimprint lithography (NIL) and metrology equipment, as well as photoresist coaters, cleaners and inspection systems.

In addition to its dominant share of the market for wafer bonders, EVG holds a leading position in NIL and lithography for advanced packaging and MEMS. Along these lines, the company co-founded the EMC-3D consortium in 2006 to create and help drive implementation of a cost-effective through-silicon via (TSV) process for major ICs and MEMS/sensors. Other target semiconductor-related markets include silicon-on-insulator (SOI), compound semiconductor and silicon-based power-device solutions.

Founded in 1980, EVG is headquartered in St. Florian, Austria, and operates via a global customer support network, with subsidiaries in Tempe, Ariz.; Albany, N.Y.; Yokohama and Fukuoka, Japan; Seoul, Korea and Chung-Li, Taiwan. The company’s unique Triple i-approach (invent – innovate – implement) is supported by a vertical integration, allowing EVG to respond quickly to new technology developments, apply the technology to manufacturing challenges and expedite device manufacturing in high volume. More information is available at www.EVGroup.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology products such as StemDisc, and specifically those systems and products that are discussed in this press release. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

SHRINK NANOTECHNOLOGIES UNVEILS VIDEOS OF STEMDISC 450 PROTOTYPE GROWING HUMAN EMBYRONIC STEM CELLS

– Targets Q1 2011 for Roll-Out of Patent-Pending Biomedical Research Tool–

CARLSBAD, CA – November 5, 2010 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed working videos of its first product offering – the StemDisc450™, a high-yield, low cost, patent-pending cell culturing biomedical research tool. Shrink expects to begin offering this product for sale in the first quarter of 2011 or sooner.

“Tissue engineering and cell culturing are high growth areas of the biotechnology field. This trend is being fueled as the idea of “personalized medicine” – or “therapeutics and treatments made for you” – becomes a reality. And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson’s and Alzheimer’s disease, and many more. StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools,” stated Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

“We are pleased to reveal a working StemDisc450 prototype, a device actually developing HESCs (human embryonic stem cells),” added Baum. “Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc™ products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States.”

The videos are available by following this link:

http://www.shrinknano.com/stem-cell-culturing/

About StemDisc

StemDisc is designed to improve embryoid body (EB) formation of stem cells at a higher rate and efficiency over current EB formation methods. The platform can be used to grow and differentiate human and animal single cells, human embryonic stem cells (HESCs) and induced pluri-potent stem cells (IPSCs). Versions of StemDisc’s unique honeycomb-like well will be offered in different diameter and depth depending on the type of cell and application. Each round bottom “microwell” is capable of making 800 to 1,000 EBs, increasing the flexibility of use for researchers to achieve optimum EB formation with high reliability compared to legacy methods. A unique feature of the StemDisc product line is the optical transparency of the surface that the cells rest in. The StemDisc polymer offers amazing transparency, providing the cell biologist with the ability to see more of what she is doing as she completes her research. StemDisc’s five micron walls between microwells virtually assure a clean transfer of the biological material into a well – in a few easy steps, helping to further lower costs and accelerate the time to publish results of potentially life-saving studies. If you are interested in receiving more information about StemDisc, please contact us by visiting www.shrinknano.com.

About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company’s unique NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.
See also:

http://www.shrinksolar.com/blog/

http://www.shrinknano.com/products/product-tools

http://www.shrinknano.com/products/product-diagnostics

http://www.shrinknano.com/tech

http://www.shrinknano.com/tr35-a-children%E2%80%99s-toy-inspires-a-cheap-easy-production-method-for-high-tech-diagnostic-chips

Contact:
For Shrink Nanotechnologies
Mark L. Baum, Esq.
760-804-8844 x205

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

Shrink announced today that it has entered into an agreement to produce a high content screening tool for its biotech R&D subsidiary, Shrink Chips LLC. Stemage™ software will launch with StemDisc products; however the long term goal of the project is to build the world’s first intuitive and integrated bio-informatics database to facilitate the acquisition and sharing of three-dimensional (3D) imaging and data to predict the best method for culturing embryoid bodies (EBs) and other cellular structures.

EBs are used to grow or regenerate stem cells and nearly any kind of tissue in the body – from muscles to eyes to lungs. EBs are used in a wide range of 2-D and 3-D cellular-based disease models for drug screening/testing, tissue engineering and personalized medicine. “The Human Genome Project, completed in 2003, ushered in one of the most profound changes to 20th century scientific research – the identification of the human genome sequence. While the sequence of human DNA is stored in databases worldwide, biologists are still struggling to interpret the data and meet the high-throughput demands of their stem cell research projects,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

StemDisc products – as hardware – will allow for the development of thousands of EBs on a single footprint well plate. The success of our ability to create “EB data points” has actually presented another problem: What does the biologist do with all of the data that is being created? How can this data be rapidly collected, analyzed and even modeled? Computing power is increasing ever rapidly.

Beginning in the first week of November, Shrink will begin testing the image acquisition aspect of the Stemage software which will allow the user to center his or her microscope over the StemDisc, press “start” and have the software locate all of the individual microwells within the StemDisc system. This system will eliminate the manual processes involved in data acquisition and will also save the user time by eliminating the need to “crop” out images and regions of interest. At the same time, additional features and protocols for staining and imaging EBs in three dimensions are being finalized. The Company believes that initial versions of the plug-in will be available at the time StemDisc is launched.

When released, Shrink’s bio-informatics tool will be downloaded as a plug-in to existing scope platforms. It is hoped that in the longer term, this project has the potential to aid in automated image analysis to extract 3D models of cell locations and concentrations of gene products of interest, eventually providing a much needed global repository for data processing, storing and analysis of specific cell culturing models. Our goal is to allow today’s disparate cell culturing models to be shared and interpreted worldwide with greater speed and efficiency, helping to drive down the costs of potentially life-saving biotech research,” added Baum.

Shrink announced today that it has entered into a licensing agreement with Corning Incorporated (NYSE:GLW – News).

In exchange for a commercial royalty, Shrink retains an exclusive right to use and sublicense Corning’s patent-pending modular microfluidic system for at least eight years.

The patent-pending Corning modular microfluidic system has been widely published and has generated significant interest from commercial and academic interests since it was first published in 2008 in Lab on a Chip, a high impact academic journal. This system is the world’s first fully functional plug and play modular microfluidics system that truly allows for integrated high PSI connectors, electronics and pumps. This system is capable of being used in numerous commercial research applications where ultra-fast microfluidic design prototyping is desired, in biochemical, biomedical and cell-based drug discovery applications to name a few. Shrink intends to develop this system as a premium microfluidic product offering throughout North America, Europe and Asia.

Click here for more information about this new system:

http://www.shrinknano.com/corning-relationship

“One of Shrink’s missions within its ShrinkChips Subsidiary is to make low cost, high quality, integrated and flexible microfluidic systems for a growing microfluidics market. In order to compliment our lower cost NanoShrink brand offerings, which will launch this year, we are pleased to be able to also design, build and offer for sale, a platform based on Corning’s patent-pending modular system, which we believe is truly unique and gives researchers unparalleled flexibility to, ‘on the fly,’ conduct important biotechnology experiments,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. Baum continued, “Corning’s Corporate Research Lab is an extremely impressive organization with tremendous resources that we believe we will be able to leverage over the coming year as we develop this unique technology. We look forward to working with Corning’s team to make this agreement a success and to get this important technology to market.”

Shrink announced today that its scientific founder, Dr. Michelle Khine, has received a multi-year and multi-million dollar grant from the National Institutes of Health (NIH) to work on her shrink-film based diagnostic platforms. In addition to the grant, she was given the NIH Director’s New Innovator Award. The core of the technology underlying this grant is being commercialized by Shrink Nanotechnologies in the form of its NanoShrink branded shrink films, StemDisc cell culturing devices as well as numerous additional products that are under development using this innovative shrink-film based platform. Shrink’s initial suites of products are slated for commercial sale later this year.

As part of NIH’s commitment to increasing opportunities for new scientists, it has created the NIH Director’s New Innovator Award, which addresses two important goals: stimulating highly innovative research and supporting promising new investigators. The award supports exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact.

The grant to Dr. Khine, $2.295 million over five years, will fund the research and development of “Shrink-Induced Manufacturing Platforms for Low-Cost Diagnostics (SIMPL-CD),” which aims to develop Khine’s existing micro- and nanofabrication technology to create microfluidic devices to detect rotavirus infections from saliva samples in children in developing countries.

Commenting on this announcement, Mark L. Baum, Shrink’s Founder and CEO stated, “NIH’s recognition of the intelligence, creativity and promise behind Dr. Khine’s work, along with MIT’s Technology Review Magazine’s TR 35 Award which Dr. Khine received last year, is more important recognition of Dr. Khine’s important work and the platform that we are working on commercializing. It is also another step forward in the growing momentum behind working with low cost, flexible and simple design platforms such as our NanoShrink platform, which was designed by and which is utilized in Dr. Khine’s lab. This award will go a long way towards fueling new innovation based on the NanoShrink platform and towards making Dr. Khine’s goal of building and commercializing low cost and flexible diagnostic tools, which have specific application for diseases that typically affect young and poor children, a reality.”

About Dr. Khine’s Technology and Lab

The challenge of micro- and nanofabrication on a large scale lies in the difficulties and costs associated with patterning the specifications of a device at an appropriately high resolution. Instead of relying on tradition fabrication techniques — largely inherited from the semiconductor industry — for microfluidic applications, Khine’s research laboratory has developed a radically different approach. Patterning is done inexpensively at the large scale using a desktop laser jet printer or a craft cutter from a hobby store. The thermoplastic sheets then relax to their pre-stressed condition when heated for a few minutes, causing the macro patterned features to also shrink.

Khine’s lab has been able to create fully functional and complete microfluidic devices with integrated nanostructures within minutes. These devices can be created for only pennies per chip, and without any dedicated costly equipment. This enables researchers to make custom microsystems on demand for a range of applications from basic biology studies, to stem cell research, to point of care diagnostic devices used to detect infectious diseases.

Shrink Nanotechnologies, Inc. is the exclusive licensee of the Khine shrink-film based technologies.

Shrink Nanotechnologies, Inc. announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign™, have been filed.

CellAlign’s key feature is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The unique design is ideal for growing biological tissues from stem cells, especially those that naturally grow in a linear fashion such as in cardiac and nerve tissues.

“CellAlign has the potential to grow sheets of living tissues that may one day act as ‘band-aids’ to patch and repair, and possibly regenerate, damaged or diseased organs,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. “Clinical practices and medical specialties are increasingly turning to cellular-based therapies to solve some of the world’s most perplexing health maladies. As our intellectual property position improved with CellAlign, future licensing potential represents a significant market opportunity for Shrink.”

In the United States, tissue engineering and cell therapy comprised a $6.9 billion market for regenerative products in 2009, and is expected to approach $32 billion by 2018, according to the 2010 MedMarket Diligence’s Report, “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.” The report says the market for cellular therapies may benefit many disorders, including degenerative and traumatic orthopedic and spine injuries, cardiac and vascular disease, neurological disorders, diabetes, inflammatory diseases, and tooth decay.

Shrink CEO and founder Mark L. Baum stated, “Over the summer, the Company has focused on turning the ideas and innovations of our scientific founder and development team into commercial products. This work has been focused on NanoShrink and StemDisc, as well as several new and important initiatives that the Company will discuss over the coming months. The ‘take-away’ news from our standpoint is that we have made significant technological and product development progress in what has been an extremely challenging economic time. We believe that the progress we have made and the innovation we have funded during a time when many small companies shuttered their doors will bode well for us as we emerge from this challenging time in our economic history; and we look forward to unveiling what we’ve been working on.”

Shrink’s Core NanoShrink Family of Products

NanoShrink is a sheeted pre-stressed polymer material that “shrinks” by up to 95% when heated. When printed on, or cut or etched into, users are able to create patterns at the “macro-scale” and then “shrink” their designs to the micro or even nano scale after heat and other treatments are applied. The resulting patterns are used as molds or even as complete systems in a myriad of commercial and even recreational uses. The NanoShrink system is extremely flexible in terms of use, low in cost and has the capability of dramatically reducing the time-to-market for prototype products in a number of large markets.

Shrink has designed its acclaimed StemDisc cell culturing devices with NanoShrink, as well as low cost microfluidic systems and numerous other artisanal biotechnology and solar energy projects. Of late, we have begun experimenting with NanoShrink by using it for printed electronics applications and as a substrate for low cost high sensitivity immunoassays. We have also begun the development of low cost, multi-use NanoShrink science kits for the K to 3^rd grade, 4^th through 8^th grade, high school and college level markets.

This year the Company decided to develop a commercial version of the NanoShrink material and to offer it for sale as a “platform” so that users could develop their own applications – similar to the model employed by Apple for its iPad and iPhone systems. Shrink envisions a community of users creating applications (or “apps”) and building a marketplace where developers’ NanoShrink-based apps can be purchased.

Shrink’s development has been recognized nationally and internationally in leading academic journals for the potential for NanoShrink.

The Company is close to releasing the initial version of the NanoShrink material to a select group of professors and researchers, and is in the final phases of evaluating commercial prototypes which are being delivered to Shrink by key suppliers. The Company expects to launch this product sometime during 2010 and make regular announcements regarding enhancements and innovations made to the NanoShrink material which will demonstrate how NanoShrink can be used for additional potential applications.

NanoShrink Tools

In order to optimize NanoShrink for certain biotech applications, our team has designed a suite of design tools for NanoShrink, including a solid-state oven, a press and other implements.

As an example, NanoShrink has different performance features which are dependent on factors during the shrinking process, including, temperature, pressure and time exposure. The suite of NanoShrink Tools will address optimizing the performance of NanoShrink material, allowing users to get more from NanoShrink.

The Company is currently evaluating commercial prototypes and is negotiating with suppliers to produce the suite of NanoShrink Tools and expects to begin commercial sales this year.

StemDisc Cell Culturing Platform

StemDisc is a unique cell culturing platform used by researchers to grow IPSCs (induced pluripotent stem cells) and (HESCs) human embryonic stem cells. In the future, the Company intends to develop the StemDisc platform to grow larger aggregated cell structures, including tissues. The market for cell culturing tools, specifically related to stem cell development tools, is growing rapidly as leading researchers in the United States and all over the world are reaching a consensus that working stem cells for regenerative therapies and to perform basic research on will be a key to finding treatments and cures for many of humankind’s most perplexing conditions and diseases.

The Company has made significant progress on StemDisc – in terms of the design of the overall system, the material it is made of, and the ability of the Company to offer additional related products to enhance the use of the system. What was an effort to build one product for one specific application in a growing market, has become the development of an entirely new cell culturing platform for the Company to use its NanoShrink material to design microstructures and microwells for numerous product applications. The Company is completing production negotiations with various suppliers and believes that the first of the StemDisc family of products will be offered for sale sometime during the last quarter of this year. Additional product and related technology announcements for this suite of StemDisc products will be forthcoming.

New Developments

The Company has been working on at least four (4) significant new lines of business, some with major industrial companies and leading universities and others which have been developed wholly by Shrink. Over the coming months, the Company intends to discuss these efforts in more detail as items become newsworthy.

Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN – News), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today the formation a new wholly-owned subsidiary, Shrink Chips LLC, which is dedicated to the commercialization of a suite of next-generation biotechnology research tools, including its patent-pending ShrinkChip Rapid Prototyping System (RPS) which is used to inexpensively and flexibly manufacture microfluidic chips, or Lab-on-a-Chip (LOC), devices as well as many other biological and chemical sensors.
LOC devices are commonly used to screen new drugs for toxicity levels, and develop new vaccines, therapeutics and novel drug therapies for some of the world’s most prevalent and challenging diseases, including cancer, diabetes, Parkinson’s and Alzheimer’s. The use of and analysis from LOC devices, especially in the case of prototyping devices, represents a high cost for R&D groups with academic and commercial organizations. Shrink believes that companies who use Shrink’s RPS solutions for initial testing, prototyping and small scale production designs will benefit from increased design flexibility with significant cost reduction.
ShrinkChips’s initial suite of products will address two arget markets:

• a desktop-sized rapid prototyping platform for use in government laboratories, academic research facilities and commercial organizations in the U.S. and abroad; and
• an “out-of-the-box” complete biotechnology test kit for use in high school biology labs through post graduate studies.
Shrink believes that the markets for the ShrinkChip RPS prototyping platform, which is “open” source, will increase over time as the system is deployed, and academic researchers begin to publish results based on work done using the system and as Shrink begins to go to market with products it has designed and commercialized using the platform.
Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. said, “Since our scientific founder, Dr. Michelle Khine, began to receive attention for her novel method of creating low cost microfluidic, biosensing and chemical sensing devices, Shrink has accumulated interest for a commercial system based on Dr. Khine’s ideas. Now that we are getting closer and closer to bringing Dr. Khine’s ideas to the market, we have formed ShrinkChips and will have a focused team working on this project, with a specific mission and the resources to pursue the commercial development of the ShrinkChip Rapid Prototyping System, ultimately accelerating the time-to-market for several new bioscience products.”
See also:
Shrink Solar
Shrink Nano Products
Shrink Nano Diagnostic Products
Shrink Nano Technologies
Shrink Nano TR35 Award